Orchestra BioMed Holdings, Inc. (OBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseOBIO / S&P 1.53% / 15.20% |
WinOBIO / S&P 986.14% / 15.00% |
LoseOBIO / S&P -53.55% / 50.40% |
| 2026-Q12/3 |
WinOBIO / S&P 2.41% / -4.33% |
WinOBIO / S&P 1033.89% / 11.30% |
LoseOBIO / S&P -45.51% / 27.70% |
| 2025-Q42/3 |
WinOBIO / S&P 67.34% / 2.65% |
WinOBIO / S&P 1169.22% / 9.00% |
LoseOBIO / S&P -32.34% / 13.40% |
| 2025-Q31/3 |
LoseOBIO / S&P -7.46% / 8.12% |
WinOBIO / S&P 6.46% / 4.61% |
LoseOBIO / S&P 13.04% / 13.45% |
| 2025-Q22/3 |
LoseOBIO / S&P -37.38% / 10.94% |
WinOBIO / S&P 41.61% / 4.83% |
WinOBIO / S&P 15.82% / 10.63% |
| 2025-Q13/3 |
WinOBIO / S&P 7.00% / -4.27% |
WinOBIO / S&P 30.23% / 4.98% |
WinOBIO / S&P 20.27% / 10.57% |
| 2024-Q41/3 |
LoseOBIO / S&P -22.18% / 2.41% |
LoseOBIO / S&P -4.42% / 5.25% |
WinOBIO / S&P 11.33% / 6.15% |
| 2024-Q30/3 |
LoseOBIO / S&P -36.93% / 5.89% |
LoseOBIO / S&P -26.49% / 5.89% |
LoseOBIO / S&P 2.55% / 6.11% |
| 2024-Q21/3 |
WinOBIO / S&P 54.65% / 4.28% |
LoseOBIO / S&P -52.15% / 5.38% |
LoseOBIO / S&P -7.06% / 5.12% |
| 2024-Q10/3 |
LoseOBIO / S&P -42.28% / 10.56% |
LoseOBIO / S&P -42.16% / 5.71% |
LoseOBIO / S&P -30.19% / 5.59% |
| 2023-Q40/3 |
LoseOBIO / S&P 4.70% / 11.69% |
LoseOBIO / S&P -21.88% / 6.81% |
LoseOBIO / S&P -35.90% / 7.78% |
| 2023-Q31/3 |
WinOBIO / S&P 24.57% / -3.27% |
LoseOBIO / S&P OBIO unavailable / 7.52% |
LoseOBIO / S&P -17.80% / -5.03% |
| 2023-Q21/3 |
LoseOBIO / S&P -64.23% / 8.74% |
LoseOBIO / S&P OBIO unavailable / 9.50% |
WinOBIO / S&P 21.43% / -8.57% |
| 2023-Q12/3 |
WinOBIO / S&P 96.09% / 7.50% |
LoseOBIO / S&P OBIO unavailable / 10.77% |
WinOBIO / S&P 236.51% / -15.69% |
| 2022-Q40/3 |
LoseOBIO / S&P 0.81% / 7.56% |
LoseOBIO / S&P OBIO unavailable / 11.88% |
LoseOBIO / S&P OBIO unavailable / -17.99% |
| 2022-Q31/3 |
WinOBIO / S&P -0.60% / -4.88% |
LoseOBIO / S&P OBIO unavailable / 13.47% |
LoseOBIO / S&P OBIO unavailable / -1.41% |
| 2022-Q21/3 |
WinOBIO / S&P 0.50% / -16.10% |
LoseOBIO / S&P OBIO unavailable / 13.71% |
LoseOBIO / S&P OBIO unavailable / 11.04% |
| 2022-Q11/3 |
WinOBIO / S&P -1.69% / -4.60% |
LoseOBIO / S&P OBIO unavailable / 15.97% |
LoseOBIO / S&P OBIO unavailable / 42.23% |
| 2021-Q40/3 |
LoseOBIO / S&P 1.92% / 11.03% |
LoseOBIO / S&P OBIO unavailable / 15.00% |
LoseOBIO / S&P OBIO unavailable / 96.40% |
| 2021-Q30/3 |
LoseOBIO / S&P -3.04% / 0.58% |
LoseOBIO / S&P OBIO unavailable / 10.77% |
LoseOBIO / S&P OBIO unavailable / 69.42% |
| 2021-Q20/3 |
LoseOBIO / S&P -8.85% / 8.55% |
LoseOBIO / S&P OBIO unavailable / 6.58% |
LoseOBIO / S&P OBIO unavailable / 51.81% |
| 2021-Q10/3 |
LoseOBIO / S&P -12.65% / 6.17% |
LoseOBIO / S&P OBIO unavailable / -1.06% |
LoseOBIO / S&P OBIO unavailable / 7.39% |
| 2020-Q41/3 |
WinOBIO / S&P 16.45% / 12.15% |
LoseOBIO / S&P OBIO unavailable / -3.72% |
LoseOBIO / S&P OBIO unavailable / -33.42% |
| 2020-Q30/3 |
LoseOBIO / S&P OBIO unavailable / 8.93% |
LoseOBIO / S&P OBIO unavailable / -2.04% |
LoseOBIO / S&P OBIO unavailable / -27.10% |
| 2020-Q20/3 |
LoseOBIO / S&P OBIO unavailable / 20.54% |
LoseOBIO / S&P OBIO unavailable / -0.46% |
LoseOBIO / S&P OBIO unavailable / -27.11% |
| 2020-Q10/3 |
LoseOBIO / S&P OBIO unavailable / -19.60% |
LoseOBIO / S&P OBIO unavailable / 3.47% |
LoseOBIO / S&P OBIO unavailable / -14.75% |
| 2019-Q40/3 |
LoseOBIO / S&P OBIO unavailable / 9.07% |
LoseOBIO / S&P OBIO unavailable / 5.36% |
LoseOBIO / S&P OBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseOBIO / S&P OBIO unavailable / 1.70% |
LoseOBIO / S&P OBIO unavailable / 5.02% |
LoseOBIO / S&P OBIO unavailable / 0.21% |
| 2019-Q20/3 |
LoseOBIO / S&P OBIO unavailable / 4.30% |
LoseOBIO / S&P OBIO unavailable / 6.64% |
LoseOBIO / S&P OBIO unavailable / 8.65% |
| 2019-Q10/3 |
LoseOBIO / S&P OBIO unavailable / 13.65% |
LoseOBIO / S&P OBIO unavailable / 8.12% |
LoseOBIO / S&P OBIO unavailable / 14.29% |
| 2018-Q40/3 |
LoseOBIO / S&P OBIO unavailable / -13.52% |
LoseOBIO / S&P OBIO unavailable / 9.05% |
LoseOBIO / S&P OBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseOBIO / S&P OBIO unavailable / 7.71% |
LoseOBIO / S&P OBIO unavailable / 10.21% |
LoseOBIO / S&P OBIO unavailable / 19.06% |
| 2018-Q20/3 |
LoseOBIO / S&P OBIO unavailable / 3.43% |
LoseOBIO / S&P OBIO unavailable / 9.03% |
LoseOBIO / S&P OBIO unavailable / 14.46% |
| 2018-Q10/3 |
LoseOBIO / S&P OBIO unavailable / -0.76% |
LoseOBIO / S&P OBIO unavailable / 7.68% |
LoseOBIO / S&P OBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseOBIO / S&P OBIO unavailable / 6.64% |
LoseOBIO / S&P OBIO unavailable / 7.03% |
LoseOBIO / S&P OBIO unavailable / 13.82% |
| 2017-Q30/3 |
LoseOBIO / S&P OBIO unavailable / 4.48% |
LoseOBIO / S&P OBIO unavailable / 5.68% |
LoseOBIO / S&P OBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseOBIO / S&P OBIO unavailable / 3.09% |
LoseOBIO / S&P OBIO unavailable / 4.83% |
LoseOBIO / S&P OBIO unavailable / 17.74% |
| 2017-Q10/3 |
LoseOBIO / S&P OBIO unavailable / 6.07% |
LoseOBIO / S&P OBIO unavailable / 3.67% |
LoseOBIO / S&P OBIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseOBIO / S&P OBIO unavailable / 3.82% |
LoseOBIO / S&P OBIO unavailable / 2.09% |
LoseOBIO / S&P OBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseOBIO / S&P OBIO unavailable / 3.85% |
LoseOBIO / S&P OBIO unavailable / 0.20% |
LoseOBIO / S&P OBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 87.18% | 20.78% |
| Annualized return | 87.18% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -47.86% | 83.14% |
| Annualized return | -12.21% | 12.86% |
10Y · 2020-08-04 to 2026-08-27
| Metric | OBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -55.18% | 319.30% |
| Annualized return | -7.71% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |